Anzeige
Meldung des Tages: Kupfer-Engpass trifft jetzt auf starke Rohstoffhausse

NeuroBo Pharmaceuticals Aktie News

Aktie
WKN:  A3E2E8 ISIN:  US64132R4048 US-Symbol:  NRBO Branche:  Professionelle Dienstleistungen Land:  USA
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Marktkapitalisierung *
2,75 Mio. €
Streubesitz
30,37%
KGV
-0,07
Index-Zuordnung
-

NeuroBo Pharmaceuticals News

02.12.25 - PR Newswire
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
MetaVia Inc. Announces 1-for-11 Reverse Stock Split PR Newswire
07.11.25 - PR Newswire
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025 PR Newswire
06.11.25 - PR Newswire
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
04.11.25 - PR Newswire
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
MetaVia to Present New Phase 1 and Pre-​Clinical Data on DA-1726 at ObesityWeek® 2025 PR Newswire
27.10.25 - PR Newswire
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting PR Newswire
20.10.25 - PR Newswire
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025 PR Newswire
14.10.25 - PR Newswire
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference PR Newswire
26.08.25 - PR Newswire
MetaVia to Present at Upcoming Investor and Industry Conferences
MetaVia to Present at Upcoming Investor and Industry Conferences PR Newswire
07.08.25 - PR Newswire
MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
06.08.25 - PR Newswire
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient PR Newswire
04.08.25 - PR Newswire
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 PR Newswire
09.07.25 - PR Newswire
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose PR ...
21.06.25 - PR Newswire
MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
MetaVia Presents Pre-​Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session PR Newswire
04.06.25 - PR Newswire
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions PR Newswire
14.05.25 - PR Newswire
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
09.05.25 - PR Newswire
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
MetaVia Announces $10.0 Million Private Placement Priced At-​The-Market under Nasdaq Rules PR Newswire
07.05.25 - PR Newswire
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-​Regulating Effects in Patients with Presumed MASH, at the EASL ...
23.04.25 - PR Newswire
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MetaVia Announces Late-​Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 PR Newswire
22.04.25 - PR Newswire
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat ...
15.04.25 - PR Newswire
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerab
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »